Emerging role of nanog in tumorigenesis and cancer stem cells

International Journal of Cancer

Volumn 135, Issue 12, 2014, Pages 2741-2748

  Santaliz Ruiz, Luis E ^a,b   Xie, Xiujie ^a,b   Old, Matthew ^a,b   Teknos, Theodoros N ^a,b   Pan, Quintin ^a,b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Cancer initiating cells; Cancer stem cells; Epithelial mesenchymal transition; Nanog; Prognostic biomarkers

Indexed keywords

HOMEODOMAIN PROTEIN; NANOG PROTEIN, HUMAN; TUMOR MARKER;

3T3 CELL LINE; ANIMAL; BREAST TUMOR; CANCER STEM CELL; CARCINOGENESIS; COLORECTAL TUMOR; CYTOLOGY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; HEAD AND NECK TUMOR; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; LUNG TUMOR; MALE; METABOLISM; MOUSE; OVARY TUMOR; PHOSPHORYLATION; PHYSIOLOGY; PROGNOSIS; PROSTATE TUMOR; SIGNAL TRANSDUCTION; STOMACH TUMOR; TREATMENT OUTCOME;

ANIMALS; BREAST NEOPLASMS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; COLORECTAL NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HOMEODOMAIN PROTEINS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MICE; NEOPLASTIC STEM CELLS; NIH 3T3 CELLS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROGNOSIS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84903710528     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28690     Document Type: Review

References (68)

1. Booth HA, Holland PW. Eleven daughters of NANOG. Genomics 2004;84:229-38.
2. Zhang J, Wang X, Li M, et al. NANOGP8 is a retrogene expressed in cancers. FEBS J 2006;273: 1723-30.
3. Jeter CR, Badeaux M, Choy G, et al. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 2009;27:993-1005.
4. Palla AR, Piazzolla D, Abad M, et al. Reprogramming activity of NANOGP8, a NANOG family member widely expressed in cancer. Oncogene, in press, doi: 10.1038/onc.2013.196.
5. Ishiguro T, Sato A, Ohata H, et al. Differential expression of nanog1 and nanogp8 in colon cancer cells. Biochem Biophys Res Commun 2012;428: 199-204.
6. Ibrahim EE, Babaei-Jadidi R, Saadeddin A, et al. Embryonic NANOG activity defines colorectal cancer stem cells and modulates through AP1- and TCF-dependent mechanisms. Stem Cells 2012;30:2076-87.
7. Sun C, Sun L, Jiang K, et al. NANOG promotes liver cancer cell invasion by inducing epithelialmesenchymal transition through NODAL/ SMAD3 signaling pathway. Int J Biochem Cell Biol 2013;45:1099-108.
8. Shan J, Shen J, Liu L, et al. Nanog regulates selfrenewal of cancer stem cells through the insulinlike growth factor pathway in human hepatocellular carcinoma. Hepatology 2012;56:1004-14.
9. Zhang J, Wang X, Chen B, et al. Expression of Nanog gene promotes NIH3T3 cell proliferation. Biochem Biophys Res Commun 2005;338:1098-1102.
10. Piestun D, Kochupurakkal BS, Jacob-Hirsch J, et al. Nanog transforms NIH3T3 cells and targets cell-type restricted genes. Biochem Biophys Res Commun 2006;343:279-85.
11. Albers AE, Chen C, Köberle B, et al. Stem cells in squamous head and neck cancer. Crit Rev Oncol Hematol 2012;81:224-40.
12. Xie X, Piao L, Cavey GS, et al. Phosphorylation of Nanog is essential to regulate Bmi1 and promote tumorigenesis. Oncogene, in press, doi: 10.1038/onc.2013.173.
13. Bourguignon LY, Peyrollier K, Xia W, et al. Hya-luronan- CD44 interaction activates stem cell marker Nanog. Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 2008;283:17635-17651.
14. Lee M, Nam EJ, Kim SW, et al. Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma. Int J Gynecol Cancer 2012;22:1489-1496.
15. Xu CX, Xu M, Tan L, et al. MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. J Biol Chem 2012;287:34970-34978.
16. Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008;68:4311-4320.
17. Hu L, McArthur C, Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 2010;102:1276-83.
18. Lagadec C, Vlashi E, Della Donna L, et al. Radia-tion- induced reprogramming of breast cancer cells. Stem Cells 2012;30:833-44.
19. Lu X, Mazur SJ, Lin T, et al. The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis. Oncogene , in press. doi: 10.1038/onc.2013.209.
20. Han J, Zhang F, Yu M, et al. RNA interferencemediated silencing of NANOG reduces cell proliferation and induces G0/G1 cell cycle arrest in breast cancer cells. Cancer Lett 2012;321:80-8.
21. Demircan B, Dyer LM, Gerace M, et al. Comparative epigenomics of human and mouse mammary tumors. Genes Chromosomes Cancer 2009;48:83-97.
22. Nagata T, Shimada Y, Sekine S, et al. Prognostic significance of NANOG and KLF4 for breast cancer. Breast Cancer 2014;21:96-101.
23. Siu MK, Wong ES, Kong DS, et al. Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. Oncogene 2012;32: 3500-9.
24. Meng HM, Zheng P, Wang XY, et al. Overexpression of Nanog predicts tumor progression and poor prognosis in colorectal cancer. Cancer Biol Ther 2010;9:295-302.
25. Zhang J, Espinoza LA, Kinders RJ, et al. NANOG modulates stemness in human colorectal cancer. Oncogene 2013;32:4397-405.
26. Lin CW, Liao MY, Lin WW, et al. Epithelial cell adhesion molecule regulates tumor initiation and tumorigenesis via activating reprogramming factors and epithelial-mesenchymal transition gene expression in colon cancer. J Biol Chem 2012;287: 39449-59.
27. Noh KH, Kim BW, Song KH, et al. Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Invest 2012;122:4077- 40793.
28. Zhang J, Wang X, Chen B, et al. The human pluripotency gene NANOG/NANOGP8 is expressed in gastric cancer and associated with tumor development. Oncol Lett 2010;1:457-63.
29. Lin T, Ding YQ, Li JM. Overexpression of nanog protein is associated with poor prognosis in gastric adenocarcinoma. Med Oncol 2012;29:878-85.
30. Takaishi S, Okumura T, Tu S, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009;27:1006-20.
31. Nishikawa S, Konno M, Hamabe A, et al. Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy. Int J Oncol 2013; 42:1437-1442.
32. Zhi QM, Chen XH, Ji J, et al. Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer. Biomed Pharmacother 2011;65: 509-15.
33. Golestaneh AF, Atashi A, Langroudi L, et al. miRNAs expressed differently in cancer stem cells and cancer cells of human gastric cancer cell line MKN-45. Cell Biochem Funct 2012;30:411-08.
34. Liu J, Ma L, Xu J, et al. Spheroid body-forming cells in the human gastric cancer cell line MKN-45 possess cancer stem cell properties. Int J Oncol 2013;42:453-459.
35. Bourguignon LY, Earle C, Wong G, et al. Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells. Oncogene 2012;31:149-60.
36. Bourguignon LY, Wong G, Earle C, et al. Hyalur-onan- CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to selfrenewal, #clonal |formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem 2012;287: 32800-24.
37. Tsai LL, Yu CC, Chang YC, et al. Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. J Oral Pathol Med 2011;40:621-8.
38. Chiou SH, Yu CC, Huang CY, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res 2008;14:4085-95.
39. Yu CC, Che YW, Chiou GY, et al. MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation. Oral Oncol 2011;47:202-210.
40. Piao L, Zhang M, Datta J, et al. Lipid-based nanoparticle delivery of Pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. Mol Ther 2012;20:1261-9.
41. Datta J, Smith A, Lang JC, et al. microRNA-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase Cε Oncogene 2012;31:4045-53.
42. Bourguignon LY, Spevak CC, Wong G, et al. Hyaluronan-CD44 interaction with protein kinase Ce promotes oncogenic signaling by the stem cell marker nanog and the production of MicroRNA- 21, leading to down-regulation of the tumor suppresor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 2009;284:26533-46.
43. Wu MJ, Jan CI, Tsay YG, et al. Elimination of head and neck cancer initiating cells through targeting glucose regulated protein78 signaling. Mol Cancer 2010;9:283.
44. Arnaudeau S, Arboit P, Bischof P, et al. Glucoseregulated protein 78: a new partner of p53 in trophoblast. Proteomics 2009;9:5316-5327.
45. Lin T, Chao C, Saito S, et al. p53 induces differentiation of mouse embryonic stem cells by suppressing nanog expression. Nat Cell Biol 2005;7: 165-71.
46. Chen C, Wei Y, Hummel M, et al. Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLos One 2011;6:e16466.
47. Chang CC, Hsu WH, Wang CC, et al. Connective tissue growth factor activates pluripotency genes and mesenchymal-epithelial transition in head and neck cancer cells. Cancer Res 2013;73:4147- 57.
48. Biddle A, Liang X, Gammon L, et al. Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res 2011;71:5317-26.
49. Shigeishi H, Biddle A, Gammon L, et al. Maintenance of stem cell self-renewal in head and neck cancers requires actions of GSK3β influenced by CD44 and RHAMM. Stem Cells, in press.
50. Wang XQ, Ng RK, Ming X, et al. Epigenetic regulation of pluripotent genes mediates stem cell features in human hepatocellular carcinoma and cancer cell lines. PLoS One 2013;8: e72435.
51. Farthing CR, Ficz G, Ng RK, et al. Global mapping of DNA methylation in mouse promoters reveals epigenetic reprogramming of pluripotency genes. PLoS Genet 2008;4:e1000116.
52. Wang P, Gao Q, Suo Z, et al. Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines. PLoS One 2013;8:e57020.
53. Leung EL, Fiscus RR, Tung JW, et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One 2010;5:e14062.
54. Hsu HS, Huang PI, Chang YL, et al. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancerderived CD133-positive cells. Cancer 2011;117: 2970-85.
55. Chiou SH, Wang ML, Chou YT, et al. Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 2010;70:10433-44.
56. Do DV, Ueda J, Messerschmidt DM, et al. A genetic and developmental pathway from STAT3 to the OCT4-NANOG circuit is essential for maintenance of ICM lineages in vivo. Genes Dev 2013;27:1378-90.
57. Pirozzi G, Tirino V, Camerlingo R, et al. Epithelial to mesenchymal transition by TGFβ-1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS One 2011;6:e21548.
58. Li XQ, Yang XL, Zhang G, et al. Nuclear betacatenin accumulation is associated with increased expression of Nanog protein and predicts poor prognosis of non-small cell lung cancer. J Transl Med 2013;11:114.
59. Le Magnen C, Bubendorf L, Ruiz C, et al. Klf4 transcription factor is expressed in the cytoplasm of prostate cancer cells. Eur J Cancer 2013;49: 955-63.
60. Jeter CR, Liu B, Liu X, et al. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene 2011;30:3833-45.
61. Kong D, Banerjee S, Ahmad A, et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 2010;5:e12445.
62. Gu G, Yuan J, Wills M, et al. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007; 67:4807-15.63.
63. Gong C, Liao H, Guo F, et al. Implication of expression of Nanog in prostate cancer cells and their stem cells. J Huazhong Univ Sci Technolog Med Sci 2012;32:242-6.
64. Liu T, Xu F, Du X, et al. Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1. Mol Cell Biochem 2010;340:265-273.
65. Heddleston JM, Li Z, Lathia JD, et al. Hypoxia inducible factors in cancer stem cells. Br J Cancer 2010;102:789-95.
66. Ma Y, Liang D, Liu J, et al. Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS One 2011;6:e29170.
67. Covello KL, Kehler J, Yu H, et al. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 2006;20:557-70.
68. Mathieu J, Zhang Z, Zhou W, et al. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res 2011;71:4640-52.